Evaluation of anxiety levels and stress coping methods of pregnant women after the Kahramanmaraş earthquake

ObjectiveNatural disasters can cause serious psychological pressures on women during pregnancy. How the mental health of pregnant women is affected after major disasters such as earthquakes and what coping methods come into play in this process is an important research topic. This study aimed to evaluate the anxiety levels and stress coping strategies of pregnant women who experienced the February 6, 2023 Kahramanmaraş earthquake.MethodsThis cross-sectional descriptive study was carried out within four months after the earthquake. A total of 118 pregnant women were included. Participants were grouped according to pregnancy trimester. Anxiety level was assessed with the Beck Anxiety Inventory and coping strategies with the Brief COPE Scale. Earthquake exposure data, including building damage and loss of relatives, were collected via structured survey.ResultsThe mean Beck Anxiety score was 15.9 ± 12.8. A significant difference was observed between trimesters (H = 19.09, p < 0.001), with anxiety declining from the first to the third trimester. Religious coping (ρ = 0.42, p < 0.001), acceptance (ρ = 0.36, p < 0.001), and behavioral avoidance (ρ = 0.36, p < 0.001) were positively correlated with anxiety. Positive reinterpretation and development showed a significant negative correlation with anxiety (ρ = −0.32, p < 0.001). Building damage category was not significantly associated with anxiety (p = 0.80).ConclusionAnxiety in post-earthquake pregnant women differs according to trimester, and individual coping styles are associated with anxiety levels. Within the scope of the variables measured in this study, positive reinterpretation showed the strongest negative association with anxiety. Approaches supporting cognitive flexibility should be prioritized in perinatal mental health interventions.

Plasma proteomic signature of the human menstrual cycle

Nature Medicine, Published online: 13 April 2026; doi:10.1038/s41591-026-04326-5

This Resource presents a large-scale analysis of nearly 3,000 circulating plasma proteins across the menstrual cycle in over 2,700 women from the UK Biobank, revealing distinct proteomic patterns across menstrual phases. This work sheds light on female reproductive biology and gynecological disorders, and provides a proteomic signature for accurate prediction of the menstrual cycle phase.

STAT+: Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill

Metastatic pancreatic cancer patients who received a targeted pill from Revolution Medicines lived nearly twice as long as patients who received chemotherapy, a striking result in a notoriously deadly and intractable malignancy. 

Patients who took the daily pill, called daraxonrasib, lived a median of 13.2 months, compared to 6.7 months for patients who received chemotherapy.

It’s “very impressive,” said Benjamin Weinberg, an associate professor of medicine at Georgetown University who was not involved in the study, in an email.

Continue to STAT+ to read the full story…

STAT+: Allogene Therapeutics’ CAR-T treatment eliminates residual cancer cells in B-cell lymphoma patients

Allogene Therapeutics said Monday that its off-the-shelf CAR-T treatment eliminated residual cancer cells in patients with B-cell lymphoma three times better than standard care — achieving the interim goal of an ongoing Phase 3 clinical trial.

While still preliminary, the new data bolster Allogene’s efforts to develop an easily administered cell therapy that, for the first time, could delay or prevent the recurrence of cancer in patients with a high risk of lymphoma relapse at the end of first-line treatment.

In the interim analysis, 58% of patients treated with the Allogene CAR-T, called cema-cel, achieved minimal residual disease, or MRD, negativity compared to 16% of patients who were observed but not treated.

Continue to STAT+ to read the full story…

STAT+: Spyre Therapeutics IBD drug shows promise in early trial

An inflammatory bowel disease treatment developed by Spyre Therapeutics succeeded in its first major test, setting the company up to compete with several large drugmakers developing new medicines for the chronic digestive condition. 

Spyre is currently running a Phase 2 trial testing three experimental ulcerative colitis drugs as standalone treatments and, eventually, as combination therapies. The company released the first batch of results Monday on one of the treatments, showing it was safe and met the primary goal of the study. 

The therapy, SPY001, targets the alpha 4 beta 7 inflammation pathway, one of the emerging avenues drugmakers are probing to reduce inflammation in the gut. In Spyre’s SKYLINE study, subjects taking SPY001 saw a 9.2 point decrease in a disease activity index. Approximately 40% of the trial subjects went into remission after 12 weeks of use. 

Continue to STAT+ to read the full story…

You have no choice in reading this article—maybe

Uri Maoz loved doing his human research, back when he was getting his PhD. He was studying a very specific topic in computational neuroscience: how the brain instructs our arms to move and how our gray matter in turn perceives that motion. 

Then his professor asked him to deliver an undergrad lecture. Maoz assumed his boss was going to tell him exactly what to do, or at least throw some PowerPoint slides his way. But no. Maoz had free rein to teach anything, as long as it was relevant to the students. “I could have gone to human brain augmentation,” he says. “Cyborgs or whatever.”

Yet that admittedly fun and borderline sci-fi topic wasn’t what popped, unbidden, into his mind. His idea, he recalls with excitement: “What neuroscience has to say about the question of free will!” 

How—or whether—humans make decisions (like, say, about what to discuss in an undergrad lecture) had been on his mind since he’d read an article in his early twenties suggesting that … maybe they didn’t. This question might naturally beget others: Had he even had a choice about whether to read that article in the first place? How would he ever know if he was responsible for making decisions in his life or if he just had the illusion of control?

“After that, there was no turning back,” says Maoz, now a professor at Chapman University, in California. He finished his PhD work in human movement, but afterward he scooted further up the neural chain to find out how desires and beliefs turn into actions—from raising an arm to choosing someone to ask out to dinner on a Friday night.

Today, Maoz is a central figure in the attempt to (sort of, maybe) answer how that neural chain functions. His research has since overturned and reinter­preted canonical neuroscience studies and united the straight-scientific and philosophical sides of the free-will question. More than anything, though, he’s succeeded in uncovering new wrinkles in the debate.

Machines and magic tricks

The concept of free will seems straightforward, but it doesn’t have a universally accepted definition. One intuitive notion is that it’s the ability to make our own decisions and take our own actions on purpose—that we control our lives. But physicists might ask if the universe is deterministic, following a preordained path, and if human choices can still happen in such a universe. 

That’s a question for them, Maoz says. What neuroscientists can do is figure out what’s going on in the brain when people make decisions. “And that’s what we’re trying to do: to understand how our wishes, desires, beliefs, turn into actions,” he says.

By the time Maoz had finished his PhD, in 2008, neuroscientific research into the question had been going on for decades. One foundational study from the 1960s showed that a hand movement—something a person seemingly decides to do—was preceded by the appearance in the brain of an electrical signal called the “readiness potential.” 

Building on that result, in the 1980s a neuroscientist named Benjamin Libet did the experiment that had first piqued Maoz’s interest in the topic—one that many, until recently, interpreted as a death knell for the concept of free will.

An electrical impulse in our brains can shed only so much light on whether we truly are the architects of our own fates.

“He just had people sit there, and whenever they feel like it, they would go like this,” says Maoz, wiggling his wrist. Libet would then ask where a rotating dot was on a screen when they first had the urge to flick. He found that the readiness potential appeared not only before they moved their hand but before they reported having the urge to move—or, in Libet’s interpretation, before they knew they were going to move. 

Studies since have confirmed the observation and shown that the readiness potential appears a second or two—and maybe, fMRI implies, up to 10 seconds—before participants report making a conscious decision. “It suggests we are essentially passengers in a self-driving car,” says Maoz. “The unconscious biological machine does all the steering, but our conscious mind sits in the driver’s seat and takes the credit.” 

Maoz initially approached his own research with variations on Libet’s experiments. He worked with epilepsy patients who already had electrodes in their brains, for clinical purposes, and was able to predict which hand they would raise before they raised it. 

Still, some of the Libet-inspired studies people were doing nagged at him. “All these results were about completely arbitrary decisions. Raise your hand whenever you feel like it,” he says. “Why? No reason.” A decision like that is quite different from, say, choosing to break up with your partner. Try telling someone they weren’t in the driver’s seat for that

The field wasn’t looking at meaningful decisions, he says—the ones that actually set the course of lives. 

Maoz began pulling in philosophers to help guide his approach. They would challenge him to confront the semantic differences between things like intention, desire, and urge. Neuroscientists have tended to lump those concepts together, but philosophers tease them apart: Desire is a want that doesn’t necessarily progress toward an action; urge carries implications of immediacy and compulsion; and intention involves committing to a plan. (Maoz has come to focus specifically on intention—including, recently, the potential intentions of AI.)

In 2017, he organized his first in a series of free-will conferences, drawing many autonomy-interested philosophers. “Thank you so much for coming,” he recalls saying at the opening of the meeting. “As if you had a choice.” One day, the crew took an excursion out on a lake. As the group munched on shrimp, someone joked that they hoped the boat didn’t sink, because everybody in the field would die. 

The comment didn’t make Maoz feel existential dread. Instead, he figured that if the whole field was already there, why not lasso them all into writing a research grant? “He just thinks what should be the next step and just has a very good ability to just make it happen,” says Liad Mudrik, a neuroscientist at Tel Aviv University and a frequent collaborator.

That ability is special among scientists, says Chapman colleague Aaron Schurger, with whom Maoz co-directs the Laboratory for Understanding Consciousness, Intentions, and Decision-Making (LUCID, appropriately). “I really think that Uri is kind of at the nexus of this field right now because he’s really, really good at bringing people together around these big ideas,” he says.

Donations and interruptions

Maoz has recently been making progress on one of the big ideas that have consistently occupied his working hours: how trivial and significant decisions play out differently in the brain. In collaborations with Mudrik, he’s parsed the neural difference between picking and choosing—their terms for arbitrary decisions and those that change your life and tug on your emotions. 

Readiness potential? Their measurements didn’t clock it ahead of choices. In 2019, Maoz and a crew published a paper measuring the electrical activity in people’s brains as they pressed a key to choose one of two nonprofits to donate $1,000 to—for real, with actual dollars. Then the researchers compared that activity with what they saw when the same group pressed a key at random to donate $500 each to two nonprofits. The team saw the readiness potential in the arbitrary decision, but not for the $1,000 question. 

Libet’s result, they concluded, doesn’t apply to the important stuff, which means readiness potential might not actually be a sign that your brain is making a choice before you’re aware of it. “If Libet would have chosen to focus on deliberate decisions, then maybe the entire debate about neuroscience proving free will to be an illusion would have been spared from us,” Mudrik says. 

Maoz’s research has spurred others to reinterpret Libet’s work. It’s “enriched my thought process a great deal,” says Bianca Ivanof, a psychologist whose dissertation scrutinized Libet’s methods. They turn out to identify readiness potential at different times depending on how the rotating-dot setup is designed, complicating the ability to compare and interpret results.

Maoz has also continued to gather data on the subject. Last year, for example, he used an EEG to measure electrical signals in people’s brains as they got ready to press a keyboard space bar. At random moments, he interrupted their preparations with an audible tone and asked them about their intentions. He saw no connection between the readiness potential and whether or not they were planning to tap the key—evidence that the potential doesn’t represent the buildup of either conscious or unconscious plans. The team did see a signal, though, in a different part of the brain when people said they were preparing to move.

So … that’s free will? Sadly, Maoz would be compelled to say Well, not exactly. An electrical impulse in our brains can shed only so much light on whether we truly are the architects of our own fates. And maybe the confusing data from neurons is actually the point. “I don’t think it is a yes-or-no question,” Maoz says. Maybe our less meaningful choices aren’t mindfully made but big ones are; maybe we have the conscious power to change an intended action, but only if our brains are in a particular state. 

Neuroscientists likely can’t figure out, on their own, if free will exists. But they can, Maoz says, parse how semantically distinct decision-making forces—desires, urges, intentions, wishes, beliefs—manifest in our brains and become actions. “That is something that we are making progress on,” he says, “and I think that that’s going to help us understand what we do control.” And perhaps also help us make peace with what we do not. 

Sarah Scoles is a freelance science journalist and author based in southern Colorado.

Job titles of the future: Wildlife first responder

Grizzly bears have made such a comeback across eastern Montana that in 2017, the state hired its first-ever prairie-based grizzly manager: wildlife biologist Wesley Sarmento. 

For some seven years, Sarmento worked to keep both the bears, which are still listed as threatened under the Endangered Species Act, and the humans, who are sprawling into once-wild spaces, out of trouble. Based in the small city of Conrad, population 2,553, he acted sort of like a first responder, trying to defuse potentially dangerous situations. He even got caught in some himself—which is why, before he left the role to pursue a PhD, he turned to drones to get the job done. 

The bear necessities

Sarmento was studying mountain goats in Glacier National Park when he first started working with bears. To better understand how goats responded to the apex predator, he dressed up in a bear costume once a week for over three years. 

When he later started as grizzly manager, he often drove long distances to push bears away from farms. Bears are drawn to spilled or leaking grains, and an open silo quickly turns into a buffet. Sarmento would typically arrive armed with a shotgun, cracker shells, and bear spray, but after he narrowly escaped getting mauled one day, he knew he had to pivot.

“In that moment,” he says, “I was like, I am gonna get myself killed.”

A bird’s-eye view

Sarmento first turned to two Airedale dogs, a breed known for deterring bears on farms, but the dogs were easily sidetracked. Meanwhile, drones were slowly becoming more common tools for biologists in a range of activities, including counting birds and mapping habitats.

He first took one into the field in 2022, when a grizzly mom and two cubs were found rummaging around in a silo outside of town. The drone’s infrared sensors helped him quickly find their location, and he used the aircraft’s sound to drive them away from the property. (Researchers suspect bears instinctively dislike the whir of blades because it sounds like a swarm of bees.) “The whole thing was so clean and controlled,” he says. “And I did it all from the safety of my truck.”

Since then, the flying machine that Sarmento bought for $4,000—a fairly simple model with a thermal camera and 30 minutes of battery life—has shown its potential for detecting grizzlies in perilous terrain he’d otherwise have to approach on foot, like dense brush or hard-to-reach river bottoms.

A new technological foundation

Now studying wildlife ecology at the University of Montana, Sarmento is hoping to design a drone campus police can use to deter black bears from school grounds. In the future, he hopes, AI image recognition might be broadly integrated into his wildlife management work—maybe even helping drones identify bears and autonomously divert them from high-traffic areas.

All this helps keep bears from learning behaviors that lead to conflict with people—which typically ends badly for the bear and is occasionally fatal for humans.

“The out-of-the-box technology doesn’t exist yet, but the hope is to keep exploring applications,” he says. “Drones are the next frontier.” 

Emily Senkosky is a writer with a master’s degree in environmental science journalism from the University of Montana.

Opinion: STAT+: Landmines await Vinay Prasad’s successor at the FDA

Vinay Prasad’s short yet two-act tenure at the FDA was wild. How does anyone follow him as the new leader of biologics oversight at the agency?

Someone I know at the FDA joked to me recently that I should be the new director of the Center for Biologics Evaluation and Research (CBER) after Prasad. I literally laughed out loud at how comical that sounded, but it got me thinking: Who would be both willing to do it and could get picked? Further, what’s awaiting them?

Prasad became a favorite punching bag of many, including the Wall Street Journal editorial board and right-wing activists like Laura Loomer. They are teed up to clobber the next person, too.

Continue to STAT+ to read the full story…